Abstract Number: 1483 • 2019 ACR/ARP Annual Meeting
Effect of Phosphodiesterase 4 Inhibition with Apremilast on Cardiometabolic Outcomes in Psoriatic Arthritis – Initial Results from the Immune Metabolic Associations in Psoriatic Arthritis (IMAPA) Study
Background/Purpose: Psoriatic arthritis (PsA) is associated with obesity and increased cardiometabolic risk. Weight loss has been noted in association with the phosphodiesterase 4 (PDE4) inhibitor…Abstract Number: 1484 • 2019 ACR/ARP Annual Meeting
The Impact of Time Since First Diagnosis on the Efficacy and Safety of Tofacitinib in Patients with Active Psoriatic Arthritis
Background/Purpose: Early identification, diagnosis, and treatment of psoriatic arthritis (PsA) is important in preventing long-term joint damage and disability, and the associated socioeconomic consequences.1 Tofacitinib…Abstract Number: 1485 • 2019 ACR/ARP Annual Meeting
Secukinumab Provides Improvement in Nail Psoriasis and Inhibition of Radiographic Progression in Psoriatic Arthritis Patients with Nail Phenotype: 52-Week Results from a Phase III Study
Background/Purpose: Nail psoriasis (PsO) is present in up to 80% in psoriatic arthritis (PsA) patients (pts) and associated with significant pain, psychosocial disability, decreased physical…Abstract Number: 1486 • 2019 ACR/ARP Annual Meeting
Infliximab Serum Trough Levels Predict Non-clinical Response in Patients with Axial Spondyloarthritis
Background/Purpose: Infliximab (Ifx) has proven to be efficacious for improving symptoms in patients with axial SpA(axSpA). Several factors may influence the pharmacokinetic-pharmacodynamic of Ifx and…Abstract Number: 1487 • 2019 ACR/ARP Annual Meeting
Impact of TNF-α Inhibitor on Lipid Profile and Atherogenic Index of Plasma in Axial Spondyloarthritis: Two-year Follow-up Data from the Catholic Axial Spondyloarthritis COhort (CASCO)
Background/Purpose: To evaluate the influence of TNF-α inhibitor on lipid profile and atherogenic index of plasma (AIP) in axial spondyloarthritis (axSpA) patients with long term…Abstract Number: 1488 • 2019 ACR/ARP Annual Meeting
Ixekizumab Demonstrates Improvement Comparable to Adalimumab Across ACR Components in Biologic-Naïve Patients with Psoriatic Arthritis
Background/Purpose: In patients (pts) with active psoriatic arthritis (PsA) and inadequate response or intolerance to conventional synthetic DMARD (csDMARD), use of a biologic DMARD (bDMARD)…Abstract Number: 1489 • 2019 ACR/ARP Annual Meeting
Impact of Apremilast on PsA Impact of Disease Core Components in Patients with a Limited Number of Active Joints: Results from a Real-World Study
Background/Purpose: Recent data suggest that patients with moderately active psoriatic arthritis (PsA) and a limited number of active joints have a high likelihood of achieving…Abstract Number: 1490 • 2019 ACR/ARP Annual Meeting
Blockage of TNFα and IL-12/23 Improves Depressive Symptoms in Patients with Psoriatic Arthritis – Analysis of Clinical Trial Data
Background/Purpose: The prevalence of depression is increased in patients with psoriatic arthritis (PsA). Little is known about the impact of effective control of inflammation on…Abstract Number: 1491 • 2019 ACR/ARP Annual Meeting
Long-term Clinical Outcome of Anti-TNF Treatment in Patients with Early Axial Spondyloarthritis: 10-year Data of the Etanercept vs. Sulfasalazin in Early Axial Spondyloarthritis Trial
Background/Purpose: Long-term data on anti-TNF treatment in patients with early axial spondyloarthritis (SpA) is scarce. The objective of this analysis was to assess the long-term…Abstract Number: 1492 • 2019 ACR/ARP Annual Meeting
Exposure-Response Analyses for Upadacitinib Efficacy and Safety in Ankylosing Spondylitis – Analyses of the SELECT-AXIS I Study
Background/Purpose: Upadacitinib, a selective inhibitor of Janus kinase 1 (JAK1), is currently being evaluated for the treatment of several autoimmune disorders, including axial spondyloarthritis (axial…Abstract Number: 1493 • 2019 ACR/ARP Annual Meeting
Improvement in the Signs and Symptoms of Psoriatic Arthritis with Ixekizumab Compared to Adalimumab in Patient Subgroups Defined by Baseline Disease Characteristics
Background/Purpose: Multiple biologic DMARD (bDMARD) treatments are available for PsA, but there is limited research that compares the safety and efficacy of these treatments. Head-to-head…Abstract Number: 1494 • 2019 ACR/ARP Annual Meeting
Guselkumab Was More Effective Than Secukinumab in Patients with Plaque Psoriasis and the Subset of Patients with Self-Reported Psoriatic Arthritis in a Randomized, Double-blind, Head-to-head Comparison Study over 1 Year
Background/Purpose: Guselkumab (GUS, an antibody against IL-23) and secukinumab (SEC, an antibody against IL-17A) are both approved for the treatment of psoriasis (PsO). Up to…Abstract Number: 1495 • 2019 ACR/ARP Annual Meeting
Real Life 12 Year Retention Rate of Subcutaneous Anti-TNF in Spondyloarthritis. Results from a Multicenter Cohort of 1170 Patients
Background/Purpose: Drug survival is used as a tool for treatment effectiveness and safety especially in real-world data. The objective of the study was to evaluate…Abstract Number: 1496 • 2019 ACR/ARP Annual Meeting
Comparative Effectiveness of Ustekinumab and TNF Inhibitors in Patients with Psoriatic Arthritis in a Real-world, Multicenter Study
Background/Purpose: Among the treatment options for PsA, IL-12/23 inhibition with ustekinumab (UST) was the first new biologic mode of action after TNF inhibitors (TNFi). Few…Abstract Number: 1497 • 2019 ACR/ARP Annual Meeting
Efficacy of Secukinumab in a US Patient Population with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies
Background/Purpose: Secukinumab (SEC), a selective inhibitor of interleukin 17A, demonstrated rapid, significant, and sustained improvement in the signs and symptoms of PsA, with a favorable…
ACR Meeting Abstracts